IRIDEX Corporation (IRIX)

Currency in USD
1.050
+0.035(+3.45%)
Closed·
1.030-0.020(-1.90%)
·
IRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.0021.060
52 wk Range
0.8691.648
Key Statistics
Prev. Close
1.05
Open
1.02
Day's Range
1.002-1.06
52 wk Range
0.869-1.648
Volume
164.47K
Average Volume (3m)
251.03K
1-Year Change
2.9412%
Book Value / Share
-0.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.750
Upside
+161.90%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

IRIDEX Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.750
(+161.90% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Alliance Global Partners
Buy3.00+185.71%-New CoverageFeb 05, 2026

IRIDEX Corporation Earnings Call Summary for Q1/2026

  • IRIDEX posted Q1 2026 EPS of -$0.03, beating forecast of -$0.05 by 40%; revenue missed at $11.8M vs. $13.17M expected (-10.4%)
  • Shares rose 2.46% aftermarket to $1.04 despite revenue shortfall, driven by investor confidence in cost management and strategic direction
  • Gross margin declined to 40% from 43% YoY due to higher manufacturing costs and supply chain disruptions; revenue remained flat vs. Q1 2025
  • Company expects positive operating cash flow for full year 2026; manufacturing transition to complete by 2027 to improve margins
  • Strategic partnerships including EyeProGPO aim to expand market access; challenges include supply chain issues and competitive pressure
Last Updated: 2026-05-19, 05:42 p/m
Read Full Transcript

Earnings

Latest Release
May 19, 2026
EPS / Forecast
-0.03 / -0.05
Revenue / Forecast
11.8M / 13.17M
EPS Revisions
Last 90 days

IRIX Income Statement

Compare IRIX to Peers and Sector

Metrics to compare
IRIX
Peers
Sector
Relationship
P/E Ratio
−4.1x−2.3x−0.5x
PEG Ratio
−0.08−0.400.00
Price/Book
−16.9x1.3x2.6x
Price / LTM Sales
0.3x1.7x3.1x
Upside (Analyst Target)
161.9%41.0%55.1%
Fair Value Upside
Unlock12.7%7.2%Unlock

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
686.88K3.95%721.23K
Other Institutional Investors
5.82M33.47%6.11M
Public Companies & Retail Investors
10.89M62.58%11.43M
Total
17.4M100.00%18.27M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Total Stock Market ETF2.31%401,852422
Vanguard Index Funds - Vanguard Extended Market ETF0.65%112,741118

People Also Watch

3.54
ZNTL
-2.48%
20.300
CUE
-5.05%
1.21
RBNE
-0.82%
1.15
RMSG
-4.96%

FAQ

What Is the IRIDEX (IRIX) Stock Price Today?

The IRIDEX stock price today is 1.050 USD.

What Stock Exchange Does IRIDEX Trade On?

IRIDEX is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for IRIDEX?

The stock symbol for IRIDEX is "IRIX."

What Is the IRIDEX Market Cap?

As of today, IRIDEX market cap is 18.270M USD.

What Is IRIDEX's Earnings Per Share (TTM)?

The IRIDEX EPS (TTM) is -0.262.

When Is the Next IRIDEX Earnings Date?

IRIDEX will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is IRIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has IRIDEX Stock Split?

IRIDEX has split 0 times.

How Many Employees Does IRIDEX Have?

IRIDEX has 93 employees.

What is the current trading status of IRIDEX (IRIX)?

As of May 20, 2026, IRIDEX (IRIX) is trading at a price of 1.050 USD, with a previous close of 1.050 USD. The stock has fluctuated within a day range of 1.002 USD to 1.060 USD, while its 52-week range spans from 0.869 USD to 1.648 USD.

What Is IRIDEX (IRIX) Price Target According to Analysts?

The average 12-month price target for IRIDEX is 2.750 USD, with a high estimate of 2.75 USD and a low estimate of 2.75 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +161.90% Upside potential.

What Is the IRIX After Hours Price?

IRIX's last after hours stock price is 1.030 USD, the stock has decreased by -0.020, or -1.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.